Premium
A Comparative Study of Dexchlorpheniramine Maleate Sustained Release Tablets and Budesonide Nasal Spray in Seasonal Allergic Rhinitis
Author(s) -
Munch E. P.,
Søborg M.,
Nørreslet T. T.,
Mygind N.
Publication year - 1983
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1983.tb02361.x
Subject(s) - budesonide , antihistamine , nasal spray , medicine , glucocorticoid , nose , anesthesia , nasal administration , asthma , gastroenterology , inhalation , pharmacology , surgery
It was the aim of the study to compare the efficacy and side effects of oral antihistamine and nasal glucocorticoid therapy in seasonal allergic rhinitis. In a double‐blind, double‐dummy, group‐comparative study, 61 adult grass pollen allergic patients were either treated with dexchlorpheniramine maleate sustained release tablets (6 mg b.d.). or with budesonide nasal spray (200 μg b.d.). After a 1‐week run‐in period, treatment was given for 3 weeks in the grass pollen season. Patients treated with budesonide showed significantly less nasal blockage than those who received dexchlorpheniramine (P<0.05), but there was no difference in the number of sneezes and nose blowings. Patients treated with budesonide used a larger quantity of antihistamine‐vasoconstrictor eye drops (P<0.01). Drowsiness occured in the group that was treated with dexchlorpheniramine, but mainly during the first week of treatment. The side effects caused by the budesonide spray were few and insignificant. The patients' overall assessment of the treatment favoured the glucocorticoid spray (P=0.06).